enGene, Inc.
NEWS
enGene announced positive results from its LEGEND Phase I/II clinical trial for treating high-grade NMIBC in patients with carcinoma in situ that are unresponsive to BCG treatment.
It’s been a busy week for biopharma companies to name a chief executive officer. Over the past week, multiple companies have selected individuals to hold the top spots and guide the growth strategies of their companies.
IN THE PRESS
JOBS